Akebia Therapeutics Files 8-K: Material Agreement, Other Events
Ticker: AKBA · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, regulation-fd, filing
Related Tickers: AKBA
TL;DR
Akebia Therapeutics (AKBA) signed a big deal and filed an 8-K. Check it out.
AI Summary
On March 19, 2025, Akebia Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other events. This filing includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate activity for Akebia Therapeutics, including a new material agreement and regulatory disclosures, which could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements and other events reported on an 8-K can introduce new risks or alter existing ones for a company.
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Registrant
- March 19, 2025 (date) — Date of earliest event reported
- 245 First Street Cambridge, Massachusetts 02142 (address) — Principal executive offices
- 617-871-2098 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Akebia Therapeutics?
The filing states that Akebia Therapeutics, Inc. entered into a material definitive agreement on March 19, 2025, but the specific details of this agreement are not provided in the provided text.
What other items are reported in this 8-K filing?
In addition to the material definitive agreement, the filing includes a Regulation FD disclosure, reports on other events, and contains financial statements and exhibits.
When was this 8-K report filed?
The 8-K report was filed as of March 20, 2025, with the earliest event reported on March 19, 2025.
What is Akebia Therapeutics' principal executive office address?
Akebia Therapeutics, Inc.'s principal executive offices are located at 245 First Street, Cambridge, Massachusetts 02142.
What is the SIC code for Akebia Therapeutics?
The Standard Industrial Classification (SIC) code for Akebia Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 regarding Akebia Therapeutics, Inc. (AKBA).